Potassium News and Research

RSS

Eat fruits and vegetables to prevent heart disease

As heart disease continues to be the leading cause of death in the United States for all adults, a new report released by the Nutrilite Health Institute, America's Phytonutrient Report: Heart Health by Color*, shows that Americans are falling short on heart-healthy phytonutrients.

17 Feb 2010

New foundational research may advance pharmacological therapies for neurological disorders

Investigators in the Hotchkiss Brain Institute, Faculty of Medicine, have made a major breakthrough in our understanding of nerve impulse generation within the brain.

17 Feb 2010

ECR Pharmaceuticals to promote Urocit-K 15mEq tablets to primary care physicians

Hi-Tech Pharmacal Co., Inc. announced today that its branded marketing subsidiary, ECR Pharmaceuticals will promote Urocit®-K 15mEq, potassium citrate extended release tablets to primary care physicians beginning in April, 2010. Hi-Tech has a license agreement with Mission Pharmacal Company, which will promote the product to Urologists.

17 Feb 2010

High-fat ketogenic diet safe and effective for controlling childhood seizures

Current and former patients treated with the high-fat ketogenic diet to control multiple, daily and severe seizures can be reassured by the news that not only is the diet effective, but it also appears to have no long-lasting side effects, say scientists at Johns Hopkins Children's Center.

17 Feb 2010

Merck announces global sales of $27.4 billion for full-year 2009

Merck & Co., Inc. today announced financial results for the fourth quarter and the full year of 2009 which include the results of legacy Schering-Plough operations from the close of the merger on Nov. 3, 2009 through Dec. 31, 2009.

16 Feb 2010

Meda publishes 2009 year-end report

“The Meda Group expects to achieve sales of about SEK 13,000 million and an EBITDA of about SEK 4,200 million for full-year 2009.”

16 Feb 2010

Researchers develop dietary supplement to offset key symptom of ageing

Researchers at McMaster University have developed a cocktail of ingredients that forestalls major aspects of the aging process.

12 Feb 2010

Cardiac arrest due to medication-induced heart rhythm disturbance: Rare but catastrophic

Hospital care providers need to be more aware that cardiac arrest from a medication-induced heart rhythm problem is a rare but potentially catastrophic event in patients, according to a joint scientific statement from the American Heart Association and American College of Cardiology.

10 Feb 2010

Low potassium levels increase risk of death in patients with heart failure and CKD

New research from the University of Alabama at Birmingham (UAB) says low potassium levels produce an increased risk of death or hospitalization in patients with heart failure and chronic kidney disease (CKD).

10 Feb 2010

Low potassium levels increase risk of death in patients with heart failure and CKD

9 Feb 2010

Unhealthy behaviors contribute to excessive number of premature deaths in U.S.

The standard American diet, combined with inactivity and other unhealthy lifestyle behaviors, contributes to an excessive number of premature deaths in this country, according to leading preventive cardiology experts speaking at the American College of Cardiology's Fourth Annual Heart of Women's Health Conference in Washington, D.C.

9 Feb 2010

AMPYRA for MS: Acorda Therapeutics announces wholesale pricing and patient assistance program

Acorda Therapeutics, Inc. today announced the wholesale acquisition cost (WAC) for AMPYRA™ (dalfampridine) Extended Release Tablets will be $1,056 per 30-day supply (60-count pill bottle), an annual cost of $12,850. AMPYRA was approved on January 22, 2010 by the U.S. Food and Drug Administration (FDA) as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. AMPYRA is expected to be available in March 2010.

3 Feb 2010

Two new studies further the understanding of molecular steps in PLC cascade

Two new studies by researchers at the University of Washington further our understanding of the molecular steps in the PLC cascade, a G protein-coupled receptor signaling mechanism that underlies a wide variety of cellular processes, including egg fertilization, hormone secretion, and the regulation of certain potassium channels.

27 Jan 2010

caprotec bioanalytics launches three new caproKits based on its CCMS technology

caprotec bioanalytics announced today the commercial launch of three new caproKits(TM), enabling the discovery, identification and characterization of proteins belonging to the groups of metallo-proteases, histon-deacetylases and GDP/GTP binding proteins.

27 Jan 2010

NPD Group names yogurt as food trend of the decade

Americans are eating more yogurt than ever before, and Dairy Council of California advises that consumers can benefit from even more culture.

25 Jan 2010

Elan Drug Technologies issues statement on FDA approval of AMPYRA

Elan Drug Technologies, a business unit of Elan Corporation, plc (NYSE: ELN) today issued the following statement regarding the U.S. Food and Drug Administration (FDA) approval of AMPYRA™ (dalfampridine) as a treatment to improve walking in patients with multiple sclerosis (MS).

25 Jan 2010

Biogen Idec's statement on FDA approval of AMPYRA

Biogen Idec today issued the following statement regarding the United States (U.S.) Food and Drug Administration (FDA) approval of AMPYRA™ (dalfampridine) to improve walking in patients with multiple sclerosis (MS).

23 Jan 2010

FDA's Ampyra approval wonderful news for people with MS experiencing walking problems

The U.S. Food and Drug Administration has approved the marketing of Ampyra™ (dalfampridine, formerly known as fampridine SR, from Acorda Therapeutics) for its ability to improve walking speed in people with any type of multiple sclerosis.

23 Jan 2010

FDA approves fampridine-SR drug for treatment of multiple sclerosis

The Food and Drug Administration has approved the drug fampridine-SR for the treatment of multiple sclerosis. Researchers at the University of Rochester Medical Center (URMC) have been evaluating the effects of the drug in MS for more than 10 years- it is the first medication shown to enhance some neurological functions in people with the disease - and their efforts helped pave the way for today's action by the FDA.

23 Jan 2010

Acorda Therapeutics receives marketing approval from FDA for AMPYRA

Acorda Therapeutics, Inc. today announced that it has received marketing approval from the U.S. Food and Drug Administration (FDA) for AMPYRA™ (dalfampridine), an oral treatment to improve walking in patients with multiple sclerosis (MS).

22 Jan 2010

Potassium News and Research

Eat fruits and vegetables to prevent heart disease

New foundational research may advance pharmacological therapies for neurological disorders

ECR Pharmaceuticals to promote Urocit-K 15mEq tablets to primary care physicians

High-fat ketogenic diet safe and effective for controlling childhood seizures

Merck announces global sales of $27.4 billion for full-year 2009

Meda publishes 2009 year-end report

Researchers develop dietary supplement to offset key symptom of ageing

Cardiac arrest due to medication-induced heart rhythm disturbance: Rare but catastrophic

Low potassium levels increase risk of death in patients with heart failure and CKD

Low potassium levels increase risk of death in patients with heart failure and CKD

Unhealthy behaviors contribute to excessive number of premature deaths in U.S.

AMPYRA for MS: Acorda Therapeutics announces wholesale pricing and patient assistance program

Two new studies further the understanding of molecular steps in PLC cascade

caprotec bioanalytics launches three new caproKits based on its CCMS technology

NPD Group names yogurt as food trend of the decade

Elan Drug Technologies issues statement on FDA approval of AMPYRA

Biogen Idec's statement on FDA approval of AMPYRA

FDA's Ampyra approval wonderful news for people with MS experiencing walking problems

FDA approves fampridine-SR drug for treatment of multiple sclerosis

Acorda Therapeutics receives marketing approval from FDA for AMPYRA

Industry Focus eBook - Cell biology (5th edition) eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News